PROPANC BIOPHARMA, INC. Earnings Per Share (Basic)
PROPANC BIOPHARMA, INC. (PPCB) reported Earnings Per Share (Basic) of -$7.09 per share for the 3-month period ending 2026-03-31, per its S-1 filed 2026-07-17.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-07-17
- PROPANC BIOPHARMA, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$7.09.
- PROPANC BIOPHARMA, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.30.
- PROPANC BIOPHARMA, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.39.
- PROPANC BIOPHARMA, INC. earnings per share, basic for the quarter ending 2025-06-30 was -$8.77, a 103.28% decline year-over-year.
- PROPANC BIOPHARMA, INC. earnings per share, basic for fiscal 2023 was -$1.80.
- PROPANC BIOPHARMA, INC. earnings per share, basic for fiscal 2022 was -$49.23.
- PROPANC BIOPHARMA, INC. earnings per share, basic for fiscal 2021 was -$0.80.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | -$7.09 S-1 · filed 2026-07-17 | -$0.28 10-Q · filed 2026-05-14 | -$1.46 derived: net income ÷ weighted average shares · filed 2026-07-17 | -$23.82 S-1 · filed 2026-07-17 | -$0.95 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | -$0.30 S-1 · filed 2026-04-10 | -$0.69 S-1 · filed 2026-04-10 | ||||||
| 2025-09-30 | -$0.39 10-Q · filed 2025-11-14 | |||||||
| 2025-06-30 | -$8.77 derived: net income ÷ weighted average shares · filed 2026-07-17 | -$182.39 derived: net income ÷ weighted average shares · filed 2026-07-17 | -$269.96 derived: net income ÷ weighted average shares · filed 2026-07-17 | -$371.22 S-1 · filed 2026-07-17 | -$14.85 10-K · filed 2025-09-29 | |||
| 2025-03-31 | -$312.46 S-1 · filed 2026-07-17 | -$12.50 10-Q · filed 2025-05-15 | -$584.78 derived: net income ÷ weighted average shares · filed 2026-07-17 | -$965.49 S-1 · filed 2026-07-17 | -$38.62 10-Q · filed 2025-05-15 | -$1133.13 derived: net income ÷ weighted average shares · filed 2026-07-17 | ||
| 2024-12-31 | -$32.23 S-1 · filed 2026-04-10 | -$67.65 S-1 · filed 2026-04-10 | -$67.64 10-Q · filed 2025-02-14 | -$156.91 derived: net income ÷ weighted average shares · filed 2026-07-17 | -$295.08 derived: net income ÷ weighted average shares · filed 2026-07-17 | |||
| 2024-09-30 | -$35.97 10-Q · filed 2025-11-14 | $0.00 10-Q · filed 2024-11-14 | -$167.58 derived: net income ÷ weighted average shares · filed 2026-07-17 | -$396.35 derived: net income ÷ weighted average shares · filed 2026-07-17 | -$757.39 derived: net income ÷ weighted average shares · filed 2026-07-17 | |||
| 2024-06-30 | $267.40 derived: net income ÷ weighted average shares · filed 2026-07-17 | $5193.53 derived: net income ÷ weighted average shares · filed 2026-07-17 | -$91202.82 derived: net income ÷ weighted average shares · filed 2026-07-17 | -$35324.35 S-1 · filed 2026-07-17 | -$0.02 10-K · filed 2024-09-30 | |||
| 2024-03-31 | -$545.79 10-Q · filed 2025-05-15 | -$0.01 10-Q · filed 2024-05-15 | -$1669.98 derived: net income ÷ weighted average shares · filed 2025-05-15 | -$3164.41 10-Q · filed 2025-05-15 | -$0.05 10-Q · filed 2024-05-15 | -$0.67 derived: net income ÷ weighted average shares · filed 2025-05-15 | ||
| 2023-12-31 | -$1559.55 10-Q · filed 2025-02-14 | -$0.03 10-Q · filed 2024-02-20 | -$3835.55 10-Q · filed 2025-02-14 | -$0.06 10-Q · filed 2024-02-20 | -$0.39 derived: net income ÷ weighted average shares · filed 2025-02-14 | -$0.66 derived: net income ÷ weighted average shares · filed 2025-02-14 | ||
| 2023-09-30 | -$0.04 10-Q · filed 2024-11-14 | -$0.18 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$0.38 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$0.60 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||||
| 2023-06-30 | -$0.22 derived: net income ÷ weighted average shares · filed 2024-09-30 | -$0.58 derived: net income ÷ weighted average shares · filed 2024-09-30 | -$0.98 derived: net income ÷ weighted average shares · filed 2024-09-30 | -$1.80 10-K · filed 2024-09-30 | ||||
| 2023-03-31 | -$0.42 10-Q · filed 2024-05-15 | $0.00 10-Q · filed 2023-05-15 | -$0.91 derived: net income ÷ weighted average shares · filed 2024-05-15 | -$2.08 10-Q · filed 2024-05-15 | $0.00 10-Q · filed 2023-05-15 | $0.10 derived: net income ÷ weighted average shares · filed 2024-05-15 | ||
| 2022-12-31 | -$0.53 10-Q · filed 2024-02-20 | $0.00 10-Q · filed 2023-02-10 | -$2.10 10-Q · filed 2024-02-20 | $0.00 10-Q · filed 2023-02-10 | $0.06 derived: net income ÷ weighted average shares · filed 2024-02-20 | $0.18 derived: net income ÷ weighted average shares · filed 2024-02-20 | ||
| 2022-09-30 | -$2.13 10-Q · filed 2023-11-14 | $0.00 10-Q · filed 2022-11-14 | $0.03 derived: net income ÷ weighted average shares · filed 2023-11-14 | $0.11 derived: net income ÷ weighted average shares · filed 2023-11-14 | $0.57 derived: net income ÷ weighted average shares · filed 2023-11-14 | |||
| 2022-06-30 | $0.01 derived: net income ÷ weighted average shares · filed 2023-09-28 | $0.05 derived: net income ÷ weighted average shares · filed 2023-09-28 | $0.31 derived: net income ÷ weighted average shares · filed 2023-09-28 | -$49.23 10-K · filed 2023-09-28 | -$0.05 10-K · filed 2022-09-28 | |||
| 2022-03-31 | -$0.01 10-Q · filed 2023-05-15 | -$0.03 derived: net income ÷ weighted average shares · filed 2023-05-15 | -$0.05 10-Q · filed 2023-05-15 | -$0.09 derived: net income ÷ weighted average shares · filed 2023-05-15 | ||||
| 2021-12-31 | -$0.02 10-Q · filed 2023-02-10 | -$0.04 10-Q · filed 2023-02-10 | -$0.10 derived: net income ÷ weighted average shares · filed 2023-02-10 | -$0.14 derived: net income ÷ weighted average shares · filed 2023-02-10 | ||||
| 2021-09-30 | -$0.02 10-Q · filed 2022-11-14 | -$0.10 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$0.17 derived: net income ÷ weighted average shares · filed 2022-11-14 | |||||
| 2021-06-30 | -$0.16 derived: net income ÷ weighted average shares · filed 2022-09-28 | -$0.30 derived: net income ÷ weighted average shares · filed 2022-09-28 | -$0.80 10-K · filed 2022-09-28 | |||||
| 2021-03-31 | -$0.12 10-Q · filed 2022-05-16 | -$0.76 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |